Shares of VIVUS, Inc. (NASDAQ:

) are lower on the session by 2.19%, trading at $6.25. Overall call volume is now running at 3.76x the daily average, wit 51% of all calls traded being purchases on the offer. 5,252 contracts have traded on the session so far. VIVUS, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutic products for underserved markets. Its investigational product pipeline includes two late-stage clinical product candidates. One of these investigational products, Qnexa, has completed Phase III clinical trials for obesity, and Phase II clinical trials for diabetes and obstructive sleep apnea.